Shareholders Turn Down Tender Offer to Take BioCanCell Private Post author:Sam Post published:December 27, 2017 Post category:BioPharma Approximately 5.9 million shares were necessary for the tender to be accepted. Source: BioSpace You Might Also Like Kitov Pharma Surges as Lead Drug Hits Goals in Phase III Test October 26, 2017 Exactech Q1 Revenue Up 6% to $69.5 Million On 21% Extremities Growth April 25, 2017 <b>Ramaswamy</b> Launches Another New Biotech to Work on Phase III-Ready Drug From Merck & Co. June 5, 2017
<b>Ramaswamy</b> Launches Another New Biotech to Work on Phase III-Ready Drug From Merck & Co. June 5, 2017
